Biosign and ALQAEM introduce UFIT(R) at the Arab Health Congress in Dubai

TORONTO, Jan. 24 /PRNewswire/ - Biosign Technologies Inc. (TSXV: BIO) and the Health Care Division of ALQAEM International (FZE) ("ALQAEM") are presenting Biosign's UFIT(R) TEN-20 at the 35th Annual Arab Health Exhibition & Congress at the Dubai World Trade Centre, United Arab Emirates, during January 24-27, 2011.

"The M.E.N.A. region is experiencing the fastest per capita growth in hypertension and type-2 diabetes", stated Peter Tassiopoulos, CEO of Biosign Technologies. "Governments, hospitals, and clinicians in the region are focused on reducing the incidence of these serious conditions. We intend to establish a leading position in that multi-billion dollar market."

UFIT(R) TEN-20 is Biosign's online monitor for blood pressure and blood glucose. The device takes the pulse at the wrist through an inflatable cuff and immediately produces blood pressure and blood glucose measurement results. All measurements are non-invasive and passive. The results are stored on Biosign's servers along with the test sample. The readings and the reports can be reviewed on a secure web portal and integrated into electronic medical records. The system has been assessed and certified as meeting the requirements of ISO 9001:2008, ISO 13485-2003, and Directive 93/42/EEC ("CE Mark").

Mr. John Rizvi, Managing Director of ALQAEM, stated: "Each year, over 66,000 professionals, from 145 countries, attend this Congress. We are excited to work directly with Biosign at such an important event and we look forward to introducing the UFIT(R) product line to customers, resellers, and medical professionals from the M.E.N.A. region."

Biosign and ALQAEM will be exhibiting at booth S1G61 during the Congress. The Arab Health Exhibition & Congress is the largest healthcare exhibition in the Middle East and the second largest healthcare event of this type in the world (please visit www.arabhealthonline.com). Established in 1975, it provides a platform for the world's leading manufacturers, wholesalers, and distributors to meet the medical and scientific community in the Middle East. The Middle East market for healthcare products and services is approximately $80 billion per year.

About Biosign Technologies Inc.

Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT(R) medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign, please visit www.biosign.com

About ALQAEM International (FZE)

ALQEAM is a diversified trading and distribution company headquartered in Sharjah, United Arab Emirates. A large potion of ALQAEM's business is healthcare focused and the company has supplied a number of high-tech product lines to hospitals in Dubai, Abu Dhabi and the other United Arab Emirates. In addition, ALQAEM directs healthcare sales teams in a number of Gulf countries. In July 2010, ALQAEM was appointed the exclusive Master Distributor for Biosign health monitoring products for 10 countries in the M.E.N.A region. For more information, please visit www.alqaemhealthcare.com

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators (www.sedar.com).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Biosign Technologies Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED